LQDA

Current Thesis

YUTREPIA (treprostinil inhalation powder) is in a textbook accelerating launch ramp, and the tape is coiling into a hard binary: United Therapeutics' '327 patent trial begins 2026-06-23. The commercial narrative is the leg we're buying — Q1 2026 (call 2026-05-11) printed YUTREPIA net sales of $129.9M, +44% sequential vs Q4'25's $90.1M, total revenue $132.9M beat $116.7M consensus, EPS $0.52 vs $0.41 est, and the company is already profitable (net income $52.9M, adj EBITDA $71.2M) inside its first year on market. This is archetype-5 (binary catalyst): a momentum ramp with a defined legal event 19 days out. Legal odds favor LQDA (SCOTUS declined to review the rulings invalidating UTHR's patents; full FDA approval from 2025-05-23 is intact; the '327 preliminary injunction was already denied).

Bull Case

• Ramp is accelerating, not plateauing — YUTREPIA net sales $129.9M in Q1'26, +44% QoQ off $90.1M (Q1 call 2026-05-11). >$0.5B annualized run-rate reached in <12 months; management states "clear line of sight to $1B net revenue in 2027."
• Share gains compounding — 23% of the inhaled-prostacyclin segment as of Q1'26; prescribers with 5+ referrals up ~25% over a two-month window. ~4,500 cumulative unique scripts / ~3,750 patients treated since the June 2025 launch.
• Analyst cluster confirmation — five PT raises within days of the print: Needham $70, HC Wainwright $67 (from [entry redacted]), Wells Fargo $62 (from [entry redacted]), Jefferies $60, BTIG $59. Consensus PT +26% to ~$63.75. Street is chasing the ramp.
• Profitable + self-funded — third consecutive profitable quarter; no dilution overhang to fund the launch.
• Pipeline optionality — 8 ongoing/planned 2026 studies incl. L606 (extended-release treprostinil, Re-Spire Ph3) extends the inhaled-prostacyclin franchise beyond YUTREPIA.

Bear Case

• Binary legal overhang — UTHR '327 patent trial (D. Del.) starts 2026-06-23. A permanent-injunction loss is the tail that disrupts the single revenue engine. Holding through it is event risk, not edge.
• Single-product concentration — YUTREPIA is ~98% of revenue; any commercial or legal stumble hits the entire thesis at once.
• Entrenched incumbent — UTHR's Tyvaso DPI is the standard of care; LQDA's gains are zero-sum vs a well-capitalized rival fighting in court and the channel.
• Easy repricing is done — +260% YoY; at $55.69 vs consensus $63.75 that's ~14% to consensus. Mean-reversion risk if Q2 ramp decelerates.
• Premium multiple — ~$4.9B market cap on a sub-$600M annualized run-rate requires the $1B/2027 trajectory to actually land.

Setup & Price Structure

• Price $55.69 (2026-06-03), off modestly from the post-print high ~$56.60 (2026-05-12). Three weeks of tight consolidation in roughly the $54–57 band after the +15.7% earnings pop on 2026-05-11.
• Post-Q1 breakout / structural support sits ~$48–50 (the pre-earnings base). Holding well above it is constructive.
• Not stretched — trading slightly below the consensus PT ($63.75) and below the lowest fresh PT ($59). No blow-off top; RSI cooled during the sideways grind. This is a coil into the June 23 binary, not a parabolic exhaustion.
• Theme state: ACCELERATING on commercials, gated by a binary legal event.

Catalyst Calendar (next 30 days)

• 2026-06-23 — UTHR '327 patent infringement trial begins (D. Del.). THE binary. Favorable outcome removes the last overhang → likely re-rate toward/above $64–70 PTs. Adverse outcome → injunction risk on the single product.
• 2026-06-03 — Jefferies Global Healthcare Conference (CEO Jeffs / CFO Kaseta, 12:45pm ET) — just passed; mine the transcript for updated TRx/share KPIs.
• Ongoing — monthly YUTREPIA script/TRx velocity (channel-check proxy). Next hard financial print is Q2'26 ~early Aug (outside the 30-day window, binary-adjacent — not an earnings-driven thesis).

What Would Change Our Mind

• Adverse '327 ruling granting UTHR a permanent injunction → EXIT_FULL immediately; thesis legally broken, do not ride down.
• Q2'26 YUTREPIA net sales < $130M (sequential decline) → ramp thesis broken; the premium evaporates.
• Weekly close below $48 (post-Q1 breakout level) → structural failure, stop out.
• Share-growth stall — inhaled-prostacyclin share fails to push past 25% and prescriber adds decelerate → MATURING→SATURATED, trim into strength.

Correlation Notes

• Inverse to UTHR (United Therapeutics) — LQDA's share gains come directly out of UTHR's Tyvaso franchise; the '327 trial is zero-sum between the two names. Don't hold both long as a "theme basket."
• Low correlation to XBI / broad biotech and to the AI-momentum complex — this is an idiosyncratic launch + legal-catalyst name. That uncorrelated alpha is good for a concentrated book.
• Single-stock event risk dominates beta — size for the June 23 binary, not the index. The position will trade on its own news flow, not SPY.

current_conviction: HIGH on the commercial ramp; the binary trial caps it below SUPREME and dictates event-aware sizing.

current_archetype: 5 — binary catalyst (patent trial) layered on an accelerating launch ramp.